# SAbR For Oligo-Progressive Renal Cell Cancer.

> **NCT03696277** · PHASE2 · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 21 (actual)

## Conditions studied

- Oligoprogressive Renal Cell Carcinoma

## Interventions

- **RADIATION:** Stereotactic ablative body radiation (SABR)

## Key facts

- **NCT ID:** NCT03696277
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-01
- **Primary completion:** 2024-01-23
- **Final completion:** 2024-01-23
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2024-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03696277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03696277, "SAbR For Oligo-Progressive Renal Cell Cancer.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03696277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*